AstraZeneca (NYSE:AZN) today touted results from a Phase III extension trial evaluating the long-term safety and efficacy of benralizumab as an add-on maintenance therapy for patients with severe eosinophilic asthma.
Benralizumab, or Fasenra, is approved as an add-on maintenance treatment for severe eosinophilic asthma in an array of countries, including the U.S., the E.U., and Japan.
Get the full story at our sister site, Drug Delivery Business News.
The post AstraZeneca touts long-term safety, efficacy data for asthma biologic appeared first on MassDevice.
from MassDevice https://ift.tt/2PQ5RXd
Cap comentari:
Publica un comentari a l'entrada